PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer

NCT05346107 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
HER2-positive Breast Cancer

Interventions

DRUG: pegylated liposomal doxorubicin (PLD) plus cyclophosphamide followed by Nab-paclitaxel (Nab-P) ,continuously combined with dual HER2 blockage

Sponsor

Xijing Hospital